ABSTRACT
The wastewater-based epidemiology approach, popular for estimating illicit drug use, has been used to evaluate lifestyle habits such as alcohol, tobacco and caffeine consumption, health biomarkers including pharmaceuticals, plasticizers and flame retardants, and recently to track SARS-CoV-2 at the population level. Equally, the number of WBE studies investigating psychoactive pharmaceuticals such as antidepressants, antipsychotics and benzodiazepines has also increased, which can be connected to the overall growth of psychological disorders worldwide. This review aims to discuss novelties in sampling techniques and analytical methodologies, including sample preparation and analysis, developed for estimating the consumption of psychoactive pharmaceuticals in defined populations. Seventy-four peer-reviewed studies monitoring psychoactive pharmaceutical consumption published since 2010 have been systematically reviewed. Its findings show that a broad range of bioanalytical methodologies is used to simultaneously measure several antidepressants, antipsychotics, benzodiazepines, and their metabolites from influent wastewater samples in low concentrations and different time periods. The application of WBE commenting on the temporal and spatial variations worldwide, showing widespread consumption, is also discussed. Despite much progress and excellent studies, there remains a need for research, and deeper knowledge is needed to reduce method uncertainty, especially since excretion rates, their transformation, and in-sewer and in-sample stability for many psychoactive pharmaceutical biomarkers are not available.
ABSTRACT
Ridesharing services do not make data of their availability (supply, utilization, idle time, and idle distance) and surge pricing publicly available. It limits the opportunities to study the spatiotemporal trends of the availability and surge pricing of these services. Only a few research studies conducted in North America analyzed these features for only Uber and Lyft. Despite the interesting observations, the results of prior works are not generalizable or reproducible because: i) the datasets collected in previous publications are spatiotemporally sensitive, i.e., previous works do not represent the current availability and surge pricing of ridesharing services in different parts of the world;and ii) the analyses presented in previous works are limited in scope (in terms of countries and ridesharing services they studied). Hence, prior works are not generally applicable to ridesharing services operating in different countries. This paper addresses the issue of ridesharing-data unavailability by presenting Ridesharing Measurement Suite (RMS). RMS removes the barrier of entry for analyzing the availability and surge pricing of ridesharing services for ridesharing users, researchers from various scientific domains, and regulators. RMS continuously collects the data of the availability and surge pricing of ridesharing services. It exposes real-time data of these services through i) graphical user interfaces and ii) public APIs to assist various stakeholders of these services and simplify the data collection and analysis process for future ridesharing research studies. To signify the utility of RMS, we deployed RMS to collect and analyze the availability and surge pricing data of 10 ridesharing services operating in nine countries for eight weeks in pre and during pandemic periods. Using the data collected and analyzed by RMS, we identify that previous articles miscalculated the utilization of ridesharing services as they did not count in the vehicles driving in multiple categories of the same service. We observe that during COVID-19, the supply of ridesharing services decreased by 54%, utilization of available vehicles increased by 6%, and a 5 × increase in the surge frequency of services. We also find that surge occurs in a small geographical region, and its intensity reduces by 50% in about 0.5 miles away from the location of a surge. We present several other interesting observations on ridesharing services' availability and surge pricing. © 2022 ACM.
ABSTRACT
Background: Exposure to ambient particulate matter pollution (APMP) is a global health issue that directly affects the human respiratory system. Thus, we estimated the spatiotemporal trends in the burden of APMP-related respiratory diseases from 1990 to 2019. Methods: Based on the Global Burden of Disease Study 2019, data on the burden of APMP-related respiratory diseases were analyzed by age, sex, cause, and location. Joinpoint regression analysis was used to analyze the temporal trends in the burden of different respiratory diseases over the 30 years. Results: Globally, in 2019, APMP contributed the most to chronic obstructive pulmonary disease (COPD), with 695.1 thousand deaths and 15.4 million disability-adjusted life years (DALYs); however, the corresponding age-standardized death and DALY rates declined from 1990 to 2019. Similarly, although age-standardized death and DALY rates since 1990 decreased by 24% and 40%, respectively, lower respiratory infections (LRIs) still had the second highest number of deaths and DALYs attributable to APMP. This was followed by tracheal, bronchus, and lung (TBL) cancer, which showed increased age-standardized death and DALY rates during the past 30 years and reached 3.78 deaths per 100,000 persons and 84.22 DALYs per 100,000 persons in 2019. Among children aged < 5 years, LRIs had a huge burden attributable to APMP, whereas for older people, COPD was the leading cause of death and DALYs attributable to APMP. The APMP-related burdens of LRIs and COPD were relatively higher among countries with low and low-middle socio-demographic index (SDI), while countries with high-middle SDI showed the highest burden of TBL cancer attributable to APMP. Conclusions: APMP contributed substantially to the global burden of respiratory diseases, posing a significant threat to human health. Effective actions aimed at air pollution can potentially avoid an increase in the PM2.5-associated disease burden, especially in highly polluted areas.